Profound Medical (NASDAQ:PROF) Releases Earnings Results, Misses Expectations By $0.02 EPS

Profound Medical (NASDAQ:PROF) released its quarterly earnings data on Thursday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02), Zacks reports. Profound Medical had a negative net margin of 171.57% and a negative return on equity of 63.03%. The firm had revenue of $9.83 million for the quarter, compared to the consensus estimate of $8.82 million.

Here are the key takeaways from Profound Medical’s conference call:

• Third-quarter revenue rose 86% year over year to $9.8 million, and gross margin improved to 78% from 74%. Net loss narrowed slightly to $7.7 million, while operating cash use fell to $5.0 million; operating expenses nevertheless increased 21% to $15.5 million.
• Profound expects 2026 revenue of at least $25 million and gross margin of 70% or higher, and says cash on hand and sales should fund operations and capital needs for at least 12 months. The company has no immediate fundraising plans, but says it may evaluate financing options.
• The TULSA-PRO installed base reached 98 systems, and the company reported its 5,000th procedure in October; its qualified pipeline totaled about $79.2 million. Management cautioned that pipeline opportunities may not convert on a predictable timeline and said improving customer utilization remains a priority.
• A new Cook Medical distribution agreement is intended to broaden system sales, while Profound will continue selling disposables and service directly to customers. Management expects the TULSA Plus program to begin contributing in the second half of 2027 and forecasts overall gross margins of 70%–75% under the agreement.
• Richard Fabian will become CEO on January 14, 2027, with Arun Menawat moving to executive chair and continuing to support strategy. Fabian identified pipeline conversion, customer utilization, and operational efficiency as key execution priorities as the company scales.

Profound Medical Stock Performance

Shares of PROF stock traded up $0.33 during mid-day trading on Friday, reaching $7.21. 322,372 shares of the company were exchanged, compared to its average volume of 358,158. Profound Medical has a fifty-two week low of $4.80 and a fifty-two week high of $8.95. The company has a market capitalization of $263.60 million, a P/E ratio of -7.75 and a beta of 0.79. The business’s 50 day simple moving average is $6.24 and its 200 day simple moving average is $6.66.

Wall Street Analysts Forecast Growth

PROF has been the subject of several research reports. Wall Street Zen raised shares of Profound Medical from a “sell” rating to a “hold” rating in a research report on Saturday, October 10th. Weiss Ratings lowered shares of Profound Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 23rd. Finally, Raymond James Financial upgraded Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 price objective for the company in a research report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Profound Medical has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Profound Medical News Roundup

Here are the key news stories impacting Profound Medical this week:

• Positive Sentiment: Profound Medical forecast at least $25 million in 2026 revenue and expects its Cook Medical distribution channel to ramp up in 2027. The outlook and expanded U.S. distribution could support future growth. Article: Profound Medical projects at least $25M 2026 revenue as Cook Medical channel ramps in 2027
• Positive Sentiment: Third-quarter revenue was $9.83 million, above the $8.82 million analyst consensus. The quarterly loss narrowed to $0.21 per share from $0.26 a year earlier. Article: Profound Medical Reports Strong Third Quarter 2026 Results
• Negative Sentiment: The quarterly loss of $0.21 per share was slightly larger than the $0.19 loss analysts expected, and the company remains unprofitable. This could temper the positive reaction to the revenue beat and growth outlook. Article: Profound Medical Reports Q3 Loss, Beats Revenue Estimates

Profound Medical Company Profile

Profound Medical Corp. is a medical-technology company focused on developing and commercializing minimally invasive, incision-free treatments for prostate disease. The company’s flagship platform, TULSA-PRO, combines magnetic resonance imaging (MRI) with robotic-controlled transurethral ultrasound to ablate targeted prostate tissue while enabling physicians to monitor treatment in real time.

TULSA-PRO is primarily used for the treatment of localized prostate cancer and other prostate conditions, including benign prostatic hyperplasia.